Tirzepatide Self-Mix Vial – 60mg
Product Overview
Tirzepatide is a synthetic 39-amino-acid peptide researched as a dual GIP and GLP-1 receptor agonist.
Where selective GLP-1 compounds act on a single incretin pathway, tirzepatide is studied for its combined activity at both receptors. Research has focused on appetite regulation, satiety, glucose metabolism, insulin signalling, lipid metabolism and body composition.
Tirzepatide is not registered as a medicine in South Africa under this presentation and has not been evaluated by SAHPRA.
Product Specifications
- Active ingredient: Tirzepatide
- Total amount: 60mg
- Format: Lyophilised powder for reconstitution
- Supplier: HD Labs
- Administration: Subcutaneous
- Regulatory status: Research use only. Not a registered medicine in South Africa and not evaluated by SAHPRA.
Receptor Activity
GIP Receptor
GIP signalling is involved in nutrient handling, insulin-related pathways, adipose-tissue metabolism and energy regulation.
GLP-1 Receptor
GLP-1 signalling is associated with appetite regulation, satiety, gastric motility and glucose metabolism.
Mechanism of Action
Research into tirzepatide examines the combined effects of:
- Reduced appetite signalling
- Increased satiety
- Slowed gastric emptying
- Glucose-dependent insulin signalling
- Lipid utilisation and adipose-tissue metabolism
- Changes in energy balance
- Body-composition pathways
Research Applications
Tirzepatide research includes:
- Appetite and satiety signalling
- Glucose metabolism
- Insulin-related pathways
- GIP and GLP-1 receptor signalling
- Lipid metabolism
- Adipose-tissue research
- Body-composition research
- Metabolic flexibility
- Weight-management research
Dosage & Administration
The following figures are the supplied product dosing reference.
Dose Escalation
| Research Period | Weekly Dose |
|---|---|
| Weeks 1–4 | 2.5mg once weekly |
| Weeks 5–8 | 5mg once weekly |
| Weeks 9–12 | 7.5mg once weekly |
| Weeks 13–16 | 10mg once weekly |
| From Week 17 | 12.5mg to 15mg once weekly |
The supplied protocol states that the dose may be adjusted according to tolerance.
Frequency
Once weekly, preferably on the same day each week.
Timing
The supplied information states that tirzepatide can be administered at any time of day, regardless of meals.
Changing the Dosing Day
The supplied protocol indicates that the weekly dosing day can be changed provided that at least 3 days have passed since the previous dose.
Administration
Tirzepatide is supplied for subcutaneous administration.
The supplied product information identifies the following general administration areas:
- Upper arms
- Abdomen/stomach
- Upper legs/thighs
Do not administer intravenously or intramuscularly.
Reconstitution
This presentation is supplied as a lyophilised powder, with bacteriostatic water included in the box, and requires reconstitution before use. Our reconstitution guide walks through it step by step. Our reconstitution calculator will work out the concentration and dose volume for the vial size and dose you are using.
- Allow the vial to reach room temperature.
- Wipe the stopper with an alcohol swab.
- Introduce the bacteriostatic water slowly against the inside wall of the vial.
- Swirl gently until dissolved. Do not shake.
- Inspect the solution. Do not use if cloudy, discoloured or containing visible particles.
- Refrigerate once reconstituted and use within the period specified by the manufacturer.
Missed Dose
According to the supplied protocol:
- If the missed dose is 5 days or less overdue, administer it when remembered and continue with the normal schedule.
- If it has been more than 5 days, skip the missed dose and resume the normal weekly schedule.
- Do not administer an additional dose to compensate for a missed dose.
Potential Effects & Considerations
The supplied information identifies gastrointestinal and metabolic effects as areas to monitor, including:
- Nausea
- Vomiting
- Diarrhoea or constipation
- Reduced appetite
- Dehydration
- Dizziness
- Changes in blood glucose
- Gastrointestinal discomfort
Severe or persistent abdominal pain warrants prompt medical assessment because pancreatic inflammation can present with significant abdominal symptoms.
Individuals researching metabolic compounds should also consider relevant glucose, metabolic and clinical parameters.
Pregnancy & Breastfeeding
The supplied product information advises against use during pregnancy and breastfeeding and recommends discussing reproductive plans with an appropriate healthcare professional.
Storage & Handling
- Store refrigerated where required, or according to the manufacturer’s specified controlled-temperature conditions.
- Never freeze.
- If stored outside refrigeration, keep in a cool, dry environment within the specified temperature range.
- Keep the vial sealed and protected from light and excessive heat.
- Keep out of reach of children.
- Do not use beyond the stated expiry date.
- Inspect the solution before use and do not use if it is cloudy, discoloured or contains visible particles.
Self-Mix Format
Tirzepatide Self-Mix Vial – 60mg is supplied as a lyophilised powder for reconstitution, which allows the researcher to select the working concentration rather than being fixed to a pre-set one.
Lyophilised material is also more stable in storage than a solution, which suits protocols run over a longer period.
Important Notice
Tirzepatide Self-Mix Vial – 60mg contains tirzepatide, a research compound investigated for dual activity at the GIP and GLP-1 receptors.
The mechanisms, applications and dosing information provided above are based on the supplied product information and research references.
For research use only. Not intended for human consumption.
